Patterns of self-care needs and interventions related to biologic response modifier therapy: fatigue as a model.
Many patients receiving biologic response modifier (BRM) therapy experience fatigue as a significant and, at times, dose-limiting side effect. For this reason, a multiinstitutional pilot study was designed to collect data about the needs and self-care interventions of patients who had undergone at least one prior treatment with a BRM and had experienced fatigue as a symptom. Information was also obtained on the extent to which the needs and self-care interventions identified by patients compared with those perceived by their family members and nurses. Of the 16 patients who participated in the study, seven were being treated with interleukin-2 (IL-2), eight with interferon alfa (IFN-alpha), and one with tumor necrosis factor (TNF). The study found no significant correlation between the degree or duration of fatigue and the BRM or dosage administered. Not surprisingly, patient and family member responses correlated fairly well. However, in several parameters, including the degree and duration of fatigue, nurses' perceptions did not correlate at all with those of the patient. While 46% of nurse responses matched those of the patient as to useful self-care interventions, only 17% of nurses accurately identified factors or events that patients perceived as worsening fatigue. Further, there was no correlation among patient, family member, and nurse responses on interventions that could be used by others to help the patient cope with fatigue. The overall results of this pilot study indicate that nurses need to be more attuned to assessing fatigue as a side effect of BRM therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Robinson
K D
KD
Department of Cancer Information and Referral Services, Pittsburgh Cancer Institute, PA.
Posner
J D
JD
D002173:Cancer Care Facilities; D005221:Fatigue / Q000139:chemically induced / Q000453:epidemiology / Q000451:nursing*; D005260:Female; D006301:Health Services Needs and Demand; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D008297:Male; D016294:Models, Nursing; D009369:Neoplasms / Q000451:nursing* / Q000503:physiopathology / Q000628:therapy; D009730:Nursing Assessment / Q000592:standards*; D015403:Nursing Evaluation Research; D010414:Pennsylvania / Q000453:epidemiology; D010865:Pilot Projects; D015203:Reproducibility of Results; D012648:Self Care
D007155:Immunologic Factors